A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab™) in High-Risk Patients with Percutaneous Coronary Intervention
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab™. We expected to obtain same results as with ReoPro in improving ischemic cardiac complications in high-risk patients who were about to undergo percutaneous coronary intervention (PCI). Patients and Methods: Patients of 19 -80 years of age with acute coronary syndrome (ACS) who were about to undergo PCI were enrolled. After screening and confirmation of eligibility, patients were randomly assigned to different groups. Clotinab™ was given to 84 patients (58.7± 10.6 years, M:F=68:16) and ReoPro (59.0±10.5 years, M:F=30:10) was given to 40 patients before PCI. The primary efficacy endpoint was the onset of major adverse cardiac event (MACE) within 30 days from day 1. The tolerability endpoints were assessed based on bleeding, thrombocytopenia, change in Hb/Hct, human antichimetric antibody development, and adverse events. Results: The number of ClotinabTM patients experiencing MACE was 0 out of 76 per protocol (PP) patients. The MACE rate was 0%, and its 95% exact CI was [0.00- 4.74%]. A major bleeding event developed in 3 patients in the ReoPro group. The probability of MACE onset in Clotinab™ was estimated to be less than 5%. There was no clinically significant result in tolerability variables. Conclusion: ClotinabTM is an effective and safe medicine in preventing ischemic cardiac complications for high-risk patients who will receive PCI.
Abstract
Purpose: This study was designed as a multicenter, randomized, open-label study to evaluate the efficacy and tolerability of Clotinab™. We expected to obtain same results as with ReoPro in improving ischemic cardiac complications in high-risk patients who were about to undergo percutaneous coronary intervention (PCI). Patients and Methods: Patients of 19 -80 years of age with acute coronary syndrome (ACS) who were about to undergo PCI were enrolled. After screening and confirmation of eligibility, patients were randomly assigned to different groups. Clotinab™ was given to 84 patients (58.7± 10.6 years, M:F=68:16) and ReoPro (59.0±10.5 years, M:F=30:10) was given to 40 patients before PCI. The primary efficacy endpoint was the onset of major adverse cardiac event (MACE) within 30 days from day 1. The tolerability endpoints were assessed based on bleeding, thrombocytopenia, change in Hb/Hct, human antichimetric antibody development, and adverse events. Results: The number of ClotinabTM patients experiencing MACE was 0 out of 76 per protocol (PP) patients. The MACE rate was 0%, and its 95% exact CI was [0.00- 4.74%]. A major bleeding event developed in 3 patients in the ReoPro group. The probability of MACE onset in Clotinab™ was estimated to be less than 5%. There was no clinically significant result in tolerability variables. Conclusion: ClotinabTM is an effective and safe medicine in preventing ischemic cardiac complications for high-risk patients who will receive PCI.
참고문헌 (28)
- Coller BS, "Platelets and thrombolytic therapy", N Engl J Med, 322, pp.33~42 (1990)
- Schömig A, "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents", N Engl J Med, 334, pp.1084~1089 (1996)
- Montalescot G, "Platelet glycoprotein IIb", IIIa inhibition with coronary stenting for acute myocardial infarction, 2001, pp.344, 1895~1903
- "Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study", Lancet, 349, pp.1429~1435 (1997)
- Inhibition of the platelet glycoprotein IIb, "IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction", Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators, 1998, pp.338, 1488~1497
- Inhibition of platelet glycoprotein IIb, "IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators", Platelet Glycoprotein IIb, N Engl J Med, pp.1998, 339[DOI]
- Kong DF, "Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb", IIIa integrin in ischemic heart disease, 1998, pp.98, 2829~2835
- Coller BS, "A new murine monoclonal antibody reports an activation-dependent change in the conformation and", or microenvironment of the platelet glycoprotein IIb, J Clin Invest, pp.1985, 76[DOI]
- Use of a monoclonal antibody directed against the platelet glycoprotein IIb, "IIIa receptor in high-risk coronary angioplasty", The EPIC Investigation, 1994, pp.330, 956~961
- Ryan TJ, "Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology", American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty), 1988, pp.78, 486~502
- Cannon CP, "American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)", J Am Coll Cardiol, 38, pp.2114~2130 (2001)
- Antman EM, "The TIMI risk score for unstable angina", non-ST elevation MI: A method for prognostication and therapeutic decision making, 2000, pp.284, 835~842
- Hamm CW, "Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators", N Engl J Med, 340, pp.1623~1629 (1999)
- Simoons ML, "Randomized trial of a GPIIb", IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group, 1994, pp.89, 596~603
- Topol EJ, "Randomised trial of coronary intervention with antibody against platelet IIb", IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators, 1994, pp.343, 881~886
- Platelet glycoprotein IIb, "IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization", The EPILOG Investigators, 1997, pp.336, 1689~1696
- International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb, "IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators", Platelet IIb, Circulation, pp.1998, 97[DOI]
- A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina, "Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators", N Engl J Med, 338, pp.1498~1505 (1998)
- Braunwald E, "ACC", AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology, J Am Coll Cardiol, pp.2002, 40[DOI]
- Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II, "Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II", Lancet, 349, pp.1422~1428 (1997)
- Effects of platelet glycoprotein IIb, "IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty", The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis, 1997, pp.96, 1445~1453
- Alexander JH, "Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT", Drugs, 56, pp.965~976 (1998)
- Kaul DK, "Monoclonal antibodies to alphaVbeta3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor", Blood, 95, pp.968~974 (2000)
- Thompson RD, "Divergent effects of platelet-endothelial cell adhesion molecule-1 and beta 3 integrin blockade on leukocyte transmigration in vivo", J Immunol, 165, pp.426~434 (2000)
- PRICE Investigators, "Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb", IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial, 2001, pp.141, 402~409
- Coons JC, "Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention", Ann Pharmacother, 39, pp.1621~1626 (2005)
- Topol EJ, "Comparison of two platelet glycoprotein IIb", IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization, 2001, pp.344, 1888~1894
- Brown DL, "Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention", Am J Cardiol, 87, pp.537~541 (2001)